Get the Stockscreener App
35.61
2.21%
0.77
Ultragenyx Pharmaceutical Inc stock is traded at $35.61, with a volume of 616.64K.
It is up +2.21% in the last 24 hours and up +1.80% over the past month.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
See More
Previous Close:
$34.84
Open:
$34.68
24h Volume:
616.64K
Relative Volume:
0.72
Market Cap:
$3.37B
Revenue:
$522.75M
Net Income/Loss:
$-558.99M
P/E Ratio:
-5.5039
EPS:
-6.47
Net Cash Flow:
$-439.53M
1W Performance:
+1.42%
1M Performance:
+1.80%
6M Performance:
-20.42%
1Y Performance:
-16.43%
1-Day Range:
$34.34
$35.67
1-Week Range:
$34.27
$37.28
52-Week Range:
$29.59
$60.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Name
Ultragenyx Pharmaceutical Inc
Sector
Industry
Phone
415-483-8800
Address
60 LEVERONI COURT, NOVATO, CA
Compare RARE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
35.61 | 3.32B | 522.75M | -558.99M | -439.53M | -6.47 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-24 | Upgrade | Goldman | Neutral → Buy |
| Apr-22-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Jun-06-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Dec-30-22 | Resumed | H.C. Wainwright | Buy |
| Nov-03-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-01-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-16-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Feb-11-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-30-21 | Initiated | H.C. Wainwright | Buy |
| Aug-19-21 | Initiated | UBS | Sell |
| Jul-15-21 | Initiated | Guggenheim | Neutral |
| Jun-29-21 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| May-06-21 | Upgrade | Citigroup | Neutral → Buy |
| May-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-02-21 | Resumed | Stifel | Buy |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-24-20 | Resumed | Evercore ISI | In-line |
| Nov-12-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-19 | Resumed | Wedbush | Outperform |
| Mar-27-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-22-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-08-18 | Upgrade | Citigroup | Sell → Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-21-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-18 | Upgrade | Barclays | Equal Weight → Overweight |
| May-10-18 | Initiated | Goldman | Neutral |
| Apr-18-18 | Upgrade | SunTrust | Hold → Buy |
| Mar-22-18 | Resumed | Piper Jaffray | Overweight |
| Feb-21-18 | Reiterated | Stifel | Buy |
| Jan-22-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-18-18 | Initiated | Credit Suisse | Outperform |
| Dec-05-17 | Reiterated | Barclays | Equal Weight |
| Dec-04-17 | Upgrade | Jefferies | Hold → Buy |
| Sep-14-17 | Upgrade | Wedbush | Neutral → Outperform |
View All
Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News
Ultragenyx Underscores Continued Commitment to Rare Disease Inno - GuruFocus
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report | RARE Stock News - GuruFocus
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report - GlobeNewswire
(RARE) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Transcript : Ultragenyx Pharmaceutical Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com
Glycogen Storage Disease Treatment Market Size in 7MM - openPR.com
RARE: Morgan Stanley Raises Price Target for Ultragenyx Pharmace - GuruFocus
Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma - insights.citeline.com
RARE: Morgan Stanley Raises Price Target for Ultragenyx Pharmaceutical | RARE Stock News - GuruFocus
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y - MSN
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2025 Earnings Call Transcript - Insider Monkey
Ultragenyx to Participate at Bank of America's 2025 Healthcare C - GuruFocus
Ultragenyx price target lowered to $100 from $140 at Truist - Yahoo Finance
Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being - simplywall.st
Truist Financial Remains a Buy on Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Ultragenyx Pharmaceutical First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Decoding Ultragenyx Pharmaceutical Inc (RARE): A Strategic SWOT Insight - GuruFocus
Ultragenyx Reports Strong Growth Amid Challenges - TipRanks
Ultragenyx to Participate at Bank of America’s 2025 Healthcare Conference - GlobeNewswire
Ultragenyx projects $640M-$670M revenue for 2025 with strong product growth - MSN
Ultragenyx (RARE) Sees Price Target Reduced Amid Gene Therapy Outlook | RARE Stock News - GuruFocus
Ultragenyx (RARE) Stock: Citi Recommends Buy Amidst Valuation In - GuruFocus
Ultragenyx (RARE) Stock: Citi Recommends Buy Amidst Valuation Insights | RARE Stock News - GuruFocus
Ultragenyx Pharmaceutical Q1 2025 Earnings Call Transcript - MarketBeat
Ultragenyx Pharmaceutical Inc (RARE) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Ultragenyx Pharmaceutical Inc (RARE) Q1 2025 Earnings Call Highl - GuruFocus
Ultragenyx Pharmaceutical Inc (RARE) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Ultragenyx: Q1 Earnings Snapshot - CTPost
Ultragenyx Reports Strong Q1 2025 Revenue Growth - TipRanks
Ultragenyx (RARE) Reports Strong Q1 2025 Revenue Growth Driven b - GuruFocus
Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Ultragenyx misses Q1 estimates, shares fall on weak results By Investing.com - Investing.com Canada
Ultragenyx misses Q1 estimates, shares fall on weak results - Investing.com
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Ultragenyx (RARE) Reports Q1 Revenue Below Expectations | RARE S - GuruFocus
Ultragenyx Pharmaceutical Inc Reports Q1 2025 Earnings: EPS of -$1.57 Beats Estimates, Revenue of $139 Million Misses Expectations - GuruFocus
Ultragenyx Pharmaceutical Q1 Loss Narrows - Nasdaq
Ultragenyx (RARE) Reaffirms FY25 Financial Outlook with Positive Revenue Growth | RARE Stock News - GuruFocus
Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update - The Manila Times
Ultragenyx May 2025 slides: pipeline advances driving path to profitability - Investing.com
Ultragenyx May 2025 slides: pipeline advances driving path to profitability By Investing.com - Investing.com South Africa
X-linked Hypophosphatemia Market 2025-2032 Business Outlook, - openPR.com
Ultragenyx Pharmaceutical's Earnings: A Preview - Nasdaq
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates - TradingView
Ultragenyx Pharmaceutical Inc expected to post a loss of $1.61 a shareEarnings Preview - TradingView
US FDA Not Industry’s ‘Sock Puppet,’ Ultragenyx’s Emil Kakkis Says - insights.citeline.com
BlackRock, Inc. Reduces Stake in Ultragenyx Pharmaceutical Inc. - GuruFocus
Ultragenyx to Host Conference Call for First Quarter 2025 Financ - GuruFocus
Ultragenyx Pharmaceutical Inc Stock (RARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):